These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15136772)

  • 21. Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
    Boiko AN; Batysheva TT; Minaeva NG; Babina LA; Vdovichenko TV; Zhuravleva EY; Shikhkerimov RK; Malykhina EA; Khozova AA; Zaitsev KA; Kostenko EV
    Neurosci Behav Physiol; 2008 Nov; 38(9):933-6. PubMed ID: 18975095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Entacapone/levodopa/carbidopa combination tablet: Stalevo.
    Drugs R D; 2003; 4(5):310-1. PubMed ID: 12952501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa/carbidopa/entacapone (Stalevo).
    Hauser RA
    Neurology; 2004 Jan; 62(1 Suppl 1):S64-71. PubMed ID: 14718682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The study on the assessment of the new levodopa drug--stalevo (levodopa/carbidopa/entacapone), in treatment of Parkinson's disease in out-patient clinical practice (the results of the open START-M)].
    Boĭko AN; Batysheva TT; Minaeva NG; Babina LA; Vdovichenko TV; Zhuravleva EIu; Shikhkerimov RK; Malykhina EA; Khozova AA; Zaĭtsev KA; Kostenko EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(12):21-4. PubMed ID: 18427455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
    Liashchenko EA; Skripkina NA; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of combining carbidopa with levodopa for Parkinson's disease.
    Martin WE; Tolosa ES; Loewenson RB; Lee MC; Resch JA; Baker AB
    Geriatrics; 1975 Dec; 30(12):39-44. PubMed ID: 1104406
    [No Abstract]   [Full Text] [Related]  

  • 28. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
    Lew MF; Somogyi M; McCague K; Welsh M;
    Int J Neurosci; 2011 Nov; 121(11):605-13. PubMed ID: 21843110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
    Delea TE; Thomas SK; Hagiwara M; Mancione L
    Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A combined preparation stalevo in Parkinson's disease: a 5-year experience of continuous dopaminergic stimulation].
    Fedotova EIu; Karabanov AV; Poleshchuk VV; Polevaia EV; Mirkasimov AF; Zagorovskaia TB; Ivanova-Smolenskaia IA; Illarioshkin SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5):50-5. PubMed ID: 22951782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sinemet CR for Parkinson's disease.
    Med Lett Drugs Ther; 1991 Oct; 33(854):92-3. PubMed ID: 1895993
    [No Abstract]   [Full Text] [Related]  

  • 32. Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.
    Novelli A; Di Vico IA; Terenzi F; Sorbi S; Ramat S
    Parkinsonism Relat Disord; 2019 Jul; 64():352-353. PubMed ID: 31101554
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 34. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].
    Levin OS; Smolentseva IG; Fedorova NV; Chigir' IP; Dokadina LV; Makhnev SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(7):27-34. PubMed ID: 18833115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Nocturnal symptoms of Parkinson's disease and approaches to their correction].
    Kulua TK; Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):62-6. PubMed ID: 24430037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
    Lombardo L; De la Garza R
    Arch Invest Med (Mex); 1977; 8(2):123-8. PubMed ID: 907417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
    Ahlskog JE
    Mayo Clin Proc; 2014 Jul; 89(7):997-1003. PubMed ID: 24996235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of non-motor fluctuations with combined drug stalevo in patients with Parkinson's disease].
    Levin OS; Ivanov AK; Shindriaeva NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(1):38-42. PubMed ID: 21350410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.